Which medications increase lipoprotein(a) levels?

Medications That Increase Lipoprotein(a) Levels

Statins are the primary medications that increase Lp(a) levels, with evidence showing elevations ranging from neutral to significant increases, despite their cardiovascular benefits through LDL-C reduction. 1

Statins: The Paradoxical Effect

The relationship between statins and Lp(a) is well-documented but paradoxical:

• Statins consistently raise or maintain elevated Lp(a) levels despite dramatically lowering LDL-C through upregulation of LDL receptors 1
• A large real-world study of 42,166 patients demonstrated statins significantly increased Lp(a) (adjusted HR 1.47; 95% CI 1.43-1.50), with a dose-dependent relationship - higher statin intensity correlated with greater Lp(a) elevation 2
• The earliest research from 1989 showed HMG-CoA reductase inhibitors increased Lp(a) by 33% while reducing LDL-C by 43% 3
• This effect is "inconsistent" per guidelines, meaning statins may cause either reduction or significant elevation 4

Clinical Implication: The Lp(a) increase with statins is particularly important because it represents unaddressed residual cardiovascular risk, even when LDL-C targets are achieved. This explains why patients with elevated Lp(a) have higher event rates at any achieved LDL-C level 1.

Growth Hormone

Growth hormone increases Lp(a) levels while paradoxically decreasing LDL-C 5:

• Lp(a) increased from 519 to 571 mg/L (P < 0.03) with growth hormone treatment
• This effect is independent of insulin-like growth factor-I (IGF-I), which actually decreases Lp(a) 5
• Growth hormone is the exception among hormones - most other hormones lower Lp(a) 1

Physiologic States That Elevate Lp(a)

While not medications, these conditions are clinically relevant:

• Pregnancy: 2.5-3-fold elevation, maximal at weeks 19-20 4
• Hypothyroidism: Elevated Lp(a) (though thyroxine replacement shows controversial effects on reduction) 4
• Nephrotic syndrome and end-stage renal disease: Significant elevations 4

Key Clinical Pitfalls

1. Don't assume statin therapy will address Lp(a) risk - it may worsen it while improving LDL-C
2. Monitor Lp(a) in patients on statins if initially elevated, as the dose-intensity relationship means higher doses may further increase levels 2
3. The cardiovascular benefit of statins persists despite Lp(a) elevation, but residual risk remains unaddressed 1

Mechanistic Understanding

The statin paradox likely occurs because:

• Lp(a) particles are poor competitors for LDL receptor binding in the presence of LDL 1
• Statins may have direct effects on Lp(a) synthesis or clearance independent of LDL receptor upregulation 3
• The modest LDLR upregulation from statins is insufficient to clear Lp(a), unlike the more robust upregulation seen with PCSK9 inhibitors (which lower Lp(a) by ~27%) 1